Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 0 | 2,500 | 10,000 | 0 | 15,277 |
| Cost of Goods | N/A | N/A | 400 | N/A | 522 |
| Gross Profit | N/A | 2,500 | 9,600 | N/A | 14,755 |
| Operating Expenses | 32,821 | 27,452 | 25,061 | 22,906 | 20,501 |
| Operating Income | -32,821 | -24,952 | -15,061 | -22,906 | -5,224 |
| Interest Expense | 815 | 684 | 706 | 633 | 544 |
| Other Income | 2,212 | 2,217 | 2,158 | 1,033 | 25 |
| Pre-tax Income | -31,424 | -23,419 | -13,609 | -22,506 | -5,743 |
| Income Tax | N/A | N/A | 0 | 5 | N/A |
| Net Income Continuous | -31,424 | -23,419 | -13,609 | -22,511 | -5,743 |
| Net Income | $-31,424 | $-23,419 | $-13,609 | $-22,511 | $-5,743 |
| EPS Basic Total Ops | -1.17 | -0.88 | -0.46 | -0.84 | -0.24 |
| EPS Basic Continuous Ops | -1.17 | -0.88 | -0.46 | -0.84 | -0.24 |
| EPS Diluted Total Ops | -1.17 | -0.88 | -0.46 | -0.84 | -0.24 |
| EPS Diluted Continuous Ops | -1.17 | -0.88 | -0.46 | -0.84 | -0.24 |
| EBITDA(a) | $-33,614 | $-26,251 | $-16,480 | $-22,438 | $-5,163 |